Solventum Corp. (SOLV)
Return on equity (ROE)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|
Net income | US$ in thousands | 692,000 | 1,343,000 | 1,460,000 | 1,138,000 |
Total stockholders’ equity | US$ in thousands | 3,409,000 | 11,742,000 | 12,059,000 | — |
ROE | 20.30% | 11.44% | 12.11% | — |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $692,000K ÷ $3,409,000K
= 20.30%
Solventum Corp.'s Return on Equity (ROE) has shown a positive trend over the years, increasing from 12.11% in 2021 to 11.44% in 2022 and further to 20.30% in 2023. This improvement indicates that the company has been effectively utilizing its shareholders' equity to generate profits. The significant jump in ROE from 2022 to 2023 suggests a notable enhancement in the company's efficiency in generating returns on equity. Overall, the increasing trend in ROE reflects positively on Solventum Corp.'s profitability and ability to create value for its shareholders.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROE
Solventum Corp.
SOLV
20.30%
3M Company
MMM
-145.52%
Artivion Inc
AORT
-10.89%
Baxter International Inc
BAX
31.61%
Becton Dickinson and Company
BDX
5.75%
Boston Scientific Corp
BSX
8.25%
DexCom Inc
DXCM
26.18%
Embecta Corp
EMBC
—
Glaukos Corp
GKOS
-29.16%
Globus Medical
GMED
3.07%
Haemonetics Corporation
HAE
12.25%